JP2018515567A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515567A5 JP2018515567A5 JP2017560686A JP2017560686A JP2018515567A5 JP 2018515567 A5 JP2018515567 A5 JP 2018515567A5 JP 2017560686 A JP2017560686 A JP 2017560686A JP 2017560686 A JP2017560686 A JP 2017560686A JP 2018515567 A5 JP2018515567 A5 JP 2018515567A5
- Authority
- JP
- Japan
- Prior art keywords
- particles
- ligands
- surrounding
- particle
- core
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 claims 26
- 239000003446 ligand Substances 0.000 claims 16
- 239000000463 material Substances 0.000 claims 13
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 210000000605 viral structure Anatomy 0.000 claims 10
- 230000003612 virological effect Effects 0.000 claims 10
- 229960005520 bryostatin Drugs 0.000 claims 9
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 9
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 9
- 102000003964 Histone deacetylase Human genes 0.000 claims 6
- 108090000353 Histone deacetylase Proteins 0.000 claims 6
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical group CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 6
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 claims 6
- MJQUEDHRCUIRLF-YCVQJEHTSA-N bryostatins Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)C([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-YCVQJEHTSA-N 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 241000700605 Viruses Species 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 230000037396 body weight Effects 0.000 claims 4
- 229960005539 bryostatin 1 Drugs 0.000 claims 3
- MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 claims 3
- 230000002209 hydrophobic effect Effects 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims 3
- 229960005184 panobinostat Drugs 0.000 claims 3
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims 3
- 229960003452 romidepsin Drugs 0.000 claims 3
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 claims 3
- 108010091666 romidepsin Proteins 0.000 claims 3
- 229960000604 valproic acid Drugs 0.000 claims 3
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 3
- 229960000237 vorinostat Drugs 0.000 claims 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562165444P | 2015-05-22 | 2015-05-22 | |
| US62/165,444 | 2015-05-22 | ||
| PCT/US2016/033766 WO2016191363A1 (en) | 2015-05-22 | 2016-05-23 | Combination hiv therapeutic |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020212055A Division JP7111795B2 (ja) | 2015-05-22 | 2020-12-22 | 組合せｈｉｖ治療薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018515567A JP2018515567A (ja) | 2018-06-14 |
| JP2018515567A5 true JP2018515567A5 (enExample) | 2019-06-27 |
| JP6816030B2 JP6816030B2 (ja) | 2021-01-20 |
Family
ID=57394156
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560686A Active JP6816030B2 (ja) | 2015-05-22 | 2016-05-23 | 組合せｈｉｖ治療薬 |
| JP2020212055A Active JP7111795B2 (ja) | 2015-05-22 | 2020-12-22 | 組合せｈｉｖ治療薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020212055A Active JP7111795B2 (ja) | 2015-05-22 | 2020-12-22 | 組合せｈｉｖ治療薬 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10493030B2 (enExample) |
| EP (1) | EP3297608B1 (enExample) |
| JP (2) | JP6816030B2 (enExample) |
| CN (1) | CN107708674A (enExample) |
| WO (1) | WO2016191363A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| EP3560492B1 (en) * | 2016-12-26 | 2023-11-29 | FUJIFILM Corporation | Lipid particle composition and pharmaceutical composition |
| US11234932B2 (en) * | 2017-11-21 | 2022-02-01 | Aphios Corporation | Combination HIV therapeutic |
| US20210163935A1 (en) * | 2019-09-05 | 2021-06-03 | Trevor P. Castor | Targeted Critical Fluid Nanoparticles Platform for Delivery of Nucleic Acids for Treatment of HIV-1 and Other Diseases |
| US20230139328A1 (en) * | 2020-03-12 | 2023-05-04 | Aphios Corporation | Dosage forms for improving organ transplantation, graft versus host disease and stem cells transplants |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2041321A4 (en) * | 2006-07-13 | 2009-12-23 | Inst Advanced Study | VIRAL INHIBITORY NUCLEOTIDE SEQUENCES AND VACCINES |
| WO2008108890A2 (en) * | 2006-10-18 | 2008-09-12 | University Of Rochester | Conditionally replicating viruses for cancer therapy |
| AT509277A1 (de) * | 2008-03-05 | 2011-07-15 | Moeller Gebaeudeautomation Gmbh | Schaltgerät |
| US20100166806A1 (en) * | 2008-12-29 | 2010-07-01 | Aphios Corporation | Combination therapy comprising the use of protein kinase C modulators and Histone Deacetylase inhibitors for treating HIV-1 latency |
| US8637074B2 (en) | 2009-03-31 | 2014-01-28 | Aphios Corporation | Methods for co-encapsulation of combination drugs and co-encapsulated combination drug product |
| EP2618843B1 (en) * | 2010-09-24 | 2016-12-07 | International Aids Vaccine Initiative | Novel hiv-1 broadly neutralizing antibodies |
| US9034347B2 (en) * | 2011-12-19 | 2015-05-19 | Arphios Corporation | Drug delivery system and method for the treatment of neuro-degenerative disease |
| WO2013165592A1 (en) * | 2012-05-03 | 2013-11-07 | Volpe Joseph M | Treatment of latent hiv infection |
| US9884026B2 (en) * | 2013-11-01 | 2018-02-06 | Yale University | Modular particles for immunotherapy |
| US11234932B2 (en) * | 2017-11-21 | 2022-02-01 | Aphios Corporation | Combination HIV therapeutic |
-
2016
- 2016-05-23 WO PCT/US2016/033766 patent/WO2016191363A1/en not_active Ceased
- 2016-05-23 JP JP2017560686A patent/JP6816030B2/ja active Active
- 2016-05-23 EP EP16800598.1A patent/EP3297608B1/en active Active
- 2016-05-23 US US15/576,190 patent/US10493030B2/en active Active
- 2016-05-23 CN CN201680029646.XA patent/CN107708674A/zh active Pending
-
2020
- 2020-12-22 JP JP2020212055A patent/JP7111795B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515567A5 (enExample) | ||
| Zhang et al. | The current landscape of the antimicrobial peptide melittin and its therapeutic potential | |
| Shi et al. | Pharmacological effects and mechanisms of bee venom and its main components: Recent progress and perspective | |
| JP2015515459A5 (enExample) | ||
| JP2016534142A5 (enExample) | ||
| HRP20220359T1 (hr) | Režim doziranja ponesimoda, selektivnog agonista receptora s1p1 | |
| JP2011529039A5 (enExample) | ||
| PH12017502326A1 (en) | Orodispersible dosage unit containing an estetrol component | |
| JP7111795B2 (ja) | 組合せｈｉｖ治療薬 | |
| JP2017533220A5 (enExample) | ||
| RU2018136872A (ru) | Композиции, содержащие 15-oh эпк, и способы их применения | |
| JP2017517551A5 (enExample) | ||
| JP2020507587A5 (enExample) | ||
| RU2018140900A (ru) | Семаглутид при сердечно-сосудистых состояниях | |
| JP2019530706A5 (enExample) | ||
| RU2019110980A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| Zielińska et al. | Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review | |
| JP2019534330A5 (enExample) | ||
| CN116744939A (zh) | At-527半硫酸盐的有利形态 | |
| JP2019504024A5 (enExample) | ||
| JP6865679B2 (ja) | 放射線で誘発された粘膜炎、食道炎、小腸炎、大腸炎、及び胃腸管急性放射線症候群を予防又は治療するための胃腸管投与多孔質消化管吸着剤ポリマーの使用 | |
| Xu et al. | Zinc oxide–selenium nanoparticles for inhibiting the proliferation of Porcine Reproductive and Respiratory Syndrome Virus | |
| JP2015044878A5 (enExample) | ||
| Liau et al. | Healing the Unhealed Wounds as the Top Priority to Save Cancer Patients | |
| JP2009505991A5 (enExample) |